Adherence to weekly oral bisphosphonate therapy: Cost of wasted drugs and fractures

Osteoporosis International

Volumn 20, Issue 9, 2009, Pages 1583-1594

  Sheehy, O ^a   Kindundu, C ^b   Barbeau, M ^b   LeLorier, J ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Novartis Pharmaceuticals Canada Inc   (Canada)

Author keywords

Adherence; Bisphosphonates; Cost of drug wasted; Economic analysis; Osteoporosis; Osteoporotic fracture

Indexed keywords

14BETA BROMOACETAMIDOMORPHINE; ALENDRONIC ACID; BENZODIAZEPINE DERIVATIVE; CALCITONIN; COCODAMOL; CODEINE; ESTROGEN; RALOXIFENE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; CANADA; COHORT ANALYSIS; DRUG COST; FEMALE; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONEY; OBSERVATIONAL STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY PREVENTION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG COSTS; FEMALE; FRACTURES, BONE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; QUEBEC; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 68949203799     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0829-2     Document Type: Article

References (45)

1. Osteoporosis Canada 2007 (2007) 2006-2007 Annual Review (Report)
2. JP Brown M Fortier H Frame A Lalonde A Papaioannou V Senikas CK Yuen 2006 Canadian consensus conference on osteoporosis, 2006 update J Obstet Gynaecol Can 28 2 Suppl 1 S95 S112
3. J Lorrain G Paiement N Chevrier G Lalumiere GH Laflamme P Caron A Fillion 2003 Population demographics and socioeconomic impact of osteoporotic fractures in Canada Menopause 10 3 228 234
4. R Lindsay RT Burge DM Strauss 2005 One year outcomes and costs following a vertebral fracture Osteoporos Int 16 1 78 85
5. CS Colon-Emeric J Caminis TT Suh CF Pieper C Janning J Magaziner J Adachi T Rosario-Jansen P Mesenbrink ZD Horowitz KW Lyles 2004 The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair Curr Med Res Opin 20 6 903 910
6. ISPOR (2003) Health care cost, quality, and outcomes
7. J Blouin A Dragomir LG Ste-Marie JC Fernandes S Perreault 2007 Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women J Clin Endocrinol Metab 92 3 887 894
8. JA Cramer DT Gold SL Silverman EM Lewiecki 2007 A systematic review of persistence and compliance with bisphosphonates for osteoporosis Osteoporos Int 18 8 1023 1031
9. TW Downey SH Foltz SJ Boccuzzi MA Omar KH Kahler 2006 Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting South Med J 99 6 570 575
10. FJ Penning-van Beest WG Goettsch JA Erkens RM Herings 2006 Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis Clin Ther 28 2 236 242
11. JY Reginster V Rabenda A Neuprez 2006 Adherence, patient preference and dosing frequency: understanding the relationship Bone 38 4 Suppl 1 S2 S6
12. CH van den Boogaard NS Breekveldt-Postma SE Borggreve WG Goettsch RM Herings 2006 Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study Curr Med Res Opin 22 9 1757 1764
13. D Weycker D Macarios J Edelsberg G Oster 2006 Compliance with drug therapy for postmenopausal osteoporosis Osteoporos Int 17 11 1645 1652
14. ES Siris ST Harris CJ Rosen CE Barr JN Arvesen TA Abbott S Silverman 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 8 1013 1022
15. JS McCombs P Thiebaud C McLaughlin-Miley J Shi 2004 Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 3 271 287
16. B Ettinger AR Pressman J Schein 1998 Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions, and discontinuation J Manag Care Pharm 4 488 492
17. JC Lo AR Pressman MA Omar B Ettinger 2006 Persistence with weekly alendronate therapy among postmenopausal women Osteoporos Int 17 6 922 928
18. DH Solomon C Morris H Cheng D Cabral JN Katz JS Finkelstein J Avorn 2005 Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions Mayo Clin Proc 80 2 194 202
19. HG Bone D Hosking JP Devogelaer JR Tucci RD Emkey RP Tonino JA Rodriguez-Portales RW Downs J Gupta AC Santora UA Liberman 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 12 1189 1199
20. MR McClung 2000 Bisphosphonates in osteoporosis: recent clinical experience Expert Opin Pharmacother 1 2 225 238
21. F Lekkerkerker JA Kanis N Alsayed G Bouvenot N Burlet D Cahall A Chines P Delmas RL Dreiser D Ethgen N Hughes JM Kaufman S Korte G Kreutz A Laslop B Mitlak V Rabenda R Rizzoli A Santora R Schimmer Y Tsouderos P Viethel JY Reginster 2007 Adherence to treatment of osteoporosis: a need for study Osteoporos Int 18 10 1311 1317
22. V Rabenda R Mertens V Fabri J Vanoverloop F Sumkay C Vannecke A Deswaef GA Verpooten JY Reginster 2008 Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women Osteoporos Int 19 6 811 818
23. KF Huybrechts KJ Ishak JJ Caro 2006 Assessment of compliance with osteoporosis treatment and its consequences in a managed care population Bone 38 6 922 928
24. JA Sunyecz L Mucha O Baser CE Barr MM Amonkar 2008 Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization Osteoporos Int 19 10 1421 1429
25. R Tamblyn G Lavoie L Petrella J Monette 1995 The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec J Clin Epidemiol 48 8 999 1009
26. R Tamblyn T Reid N Mayo P McLeod M Churchill-Smith 2000 Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment J Clin Epidemiol 53 2 183 194
27. E Garbe J Lelorier JF Boivin S Suissa 1997 Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids Lancet 350 9083 979 982
28. D Pilon AM Castilloux M Dorais J Lelorier 2004 Oral anticoagulants and the risk of osteoporotic fractures among elderly Pharmacoepidemiol Drug Saf 13 5 289 294
29. C Quach JP Collet J Lelorier 2005 Effectiveness of amoxicillin, azithromycin, cefprozil and clarithromycin in the treatment of acute otitis media in children: a population-based study Pharmacoepidemiol Drug Saf 14 3 163 170
30. E Rahme D Pettitt J Lelorier 2002 Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population Arthritis Rheum 46 11 3046 3054
31. A Rakel O Sheehy E Rahme J Lelorier 2007 Does diabetes increase the risk for fractures after solid organ transplantation? A nested case-control study J Bone Miner Res 22 1878 1884
32. R Sikka F Xia RE Aubert 2005 Estimating medication persistency using administrative claims data Am J Manag Care 11 7 449 457
33. SJ Billups DC Malone BL Carter 2000 The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs Pharmacotherapy 20 8 941 949
34. RR Recker R Gallagher PE MacCosbe 2005 Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women Mayo Clin Proc 80 7 856 861
35. H Cardinal AA Monfared M Dorais J Lelorier 2006 The concept of the 'percent wasted patients' in preventive health strategies Pharmacoepidemiol Drug Saf 15 1 57 61
36. Coyle D, Hadj Tahar A, Murphy G (2006) Teriparatide and bisphosphonates for treatment of oesteoporosis in women: a clinical and economic analysis. Canadian Agency for Drugs and Technologies in Health (CADTH). Report Issue 70, 55 (Report)
37. ME Wiktorowicz R Goeree A Papaioannou JD Adachi E Papadimitropoulos 2001 Economic implications of hip fracture: health service use, institutional care and cost in Canada Osteoporos Int 12 4 271 278
38. M Cree CL Soskolne E Belseck J Hornig JE McElhaney R Brant M Suarez-Almazor 2000 Mortality and institutionalization following hip fracture J Am Geriatr Soc 48 3 283 288
39. R Goeree B O'Brien D Pettitt L Cuddy M Ferraz JD Adachi 1996 An assessment of the burden of illness due to osteoporosis in Canada J Soc Obstet Gynaecol Can 18 Suppl 15 24
40. R Goeree G Blackhouse J Adachi 2006 Cost-effectiveness of alternative treatments for women with osteoporosis in Canada Curr Med Res Opin 22 7 1425 1436
41. Statistics Canada (2007) Consumer price index, by province. Internet communication
42. M Von Korff EH Wagner K Saunders 1992 A chronic disease score from automated pharmacy data J Clin Epidemiol 45 2 197 203
43. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 9041 1535 1541
44. DM Black DE Thompson DC Bauer K Ensrud T Musliner MC Hochberg MC Nevitt S Suryawanshi SR Cummings 2000 Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group J Clin Endocrinol Metab 85 11 4118 4124
45. JD Ringer 2008 Differences in efficacy and safety of generic and original branded once weekly bisphosphonates in postmenopausal women with osteoporosis Osteoporosis International 19 S24 S25